A Novel Enzymatic Method for Measuring Mizoribine 5′-Monophosphate Levels in Serum

Journal of Bioscience and Bioengineering

Volumn 106, Issue 5, 2008, Pages 511-514

  Ota, Hiroko ^a   Yasuda, Yuko ^a   Sakasegawa, Shin Ichi ^a   Imamura, Shigeyuki ^a   Tamura, Tomohiro ^b,c  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bacillus subtilis; inosine 5 monophosphate dehydrogenase; mizoribine; mizoribine 5 monophosphate; Oceanobacillus iheyensis

Indexed keywords

BODY FLUIDS; ENZYMES;

ACTIVE METABOLITES; BACILLUS SUBTILIS; COEFFICIENTS OF VARIATIONS; IMMUNOSUPPRESSIVE AGENTS; MIZORIBINE; OCEANOBACILLUS IHEYENSIS; SENSITIVE METHODS; SERUM SAMPLES;

BACTERIOLOGY;

DRUG METABOLITE; INOSINATE DEHYDROGENASE; MIZORIBINE 5' MONOPHOSPHATE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANALYZER; ARTICLE; BACILLUS; BACILLUS SUBTILIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYMATIC ASSAY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HETEROLOGOUS EXPRESSION; HUMAN; NONHUMAN; NORMAL HUMAN; OCEANOBACILLUS IHEYENSIS;

AUTOMATION; BACILLUS; BACILLUS SUBTILIS; BIOCHEMISTRY; BIOTECHNOLOGY; BLOOD CHEMICAL ANALYSIS; CATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; RECOMBINANT PROTEINS; RIBONUCLEOSIDES;

BACILLUS SUBTILIS; OCEANOBACILLUS IHEYENSIS;

EID: 55949088666     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1263/jbb.106.511     Document Type: Article

References (20)

1. Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr. Int. 44 (2002) 196-198
2. Stypinski D., Obaidi M., Combs M., Weber M., Stewart A.J., and Ishikawa H. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br. J. Clin. Pharmacol. 63 (2007) 459-468
3. Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr. Int. 44 (2002) 205-209
4. Jackson R.C., Weber G., and Morris H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256 (1975) 331-333
5. Weber G., Prajda N., and Jackson R.C. Key enzymes of IMP metabolism: transformation and proliferation-linked alterations in gene expression. Adv. Enzyme Regul. 14 (1976) 3-24
6. Chen L., and Pankiewicz K.W. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr. Opin. Drug Discov. Devel. 10 (2007) 403-412
7. Hedstrom L., and Gan L. IMP dehydrogenase: structural schizophrenia and an unusual base. Curr. Opin. Chem. Biol. 10 (2006) 520-525
8. Hedstrom L. IMP dehydrogenase: mechanism of action and inhibition. Curr. Med. Chem. 6 (1999) 545-560
9. Jager W., Salamon A., and Szekeres T. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. Curr. Med. Chem. 9 (2002) 781-786
10. Gan L., Seyedsayamdost M.R., Shuto S., Matsuda A., Petsko G.A., and Hedstrom L. The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase. Biochemistry 42 (2003) 857-863
11. Hosotsubo H., Takahara S., and Taenaka N. Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J. Chromatogr. 432 (1988) 340-345
12. Hager P.W., Collart F.R., Huberman E., and Mitchell B.S. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Biochem. Pharmacol. 49 (1995) 1323-1329
13. Okada M., Shimura K., Shiraki H., and Nakagawa H. IMP dehydrogenase. II. Purification and properties of the enzyme from Yoshida sarcoma ascites tumor cells. J. Biochem. (Tokyo) 94 (1983) 1605-1613
14. Sambrook J., and Russell D. Molecular cloning: a laboratory manual. 3rd ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY chapter 9
15. Colby T.D., Vanderveen K., Strickler M.D., Markham G.D., and Goldstein B.M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. USA 96 (1999) 3531-3536
16. Wang W., and Hedstrom L. Kinetic mechanism of human inosine 5′-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry 36 (1997) 8479-8483
17. Xiang B., Taylor J.C., and Markham G.D. Monovalent cation activation and kinetic mechanism of inosine 5′-monophosphate dehydrogenase. J. Biol. Chem. 271 (1996) 1435-1440
18. Wu T.W., and Scrimgeour K.G. Properties of inosinic acid dehydrogenase from Bacillus subtilis. II. Kinetic properties. Can. J. Biochem. 51 (1973) 1391-1398
19. Carr S.F., Papp E., Wu J.C., and Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268 (1993) 27286-27290
20. Digits J.A., and Hedstrom L. Kinetic mechanism of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase. Biochemistry 38 (1999) 2295-2306